These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19377078)

  • 1. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.
    Girodon F; Bonicelli G; Schaeffer C; Mounier M; Carillo S; Lafon I; Carli PM; Janoray I; Ferrant E; Maynadié M
    Haematologica; 2009 Jun; 94(6):865-9. PubMed ID: 19377078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.
    Heudes D; Carli PM; Bailly F; Milan C; Mugneret F; Petrella T
    Nouv Rev Fr Hematol (1978); 1989; 31(5):375-8. PubMed ID: 2587208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Leone G; Foà R; Larocca LM
    Blood; 2007 Nov; 110(9):3384-6. PubMed ID: 17644735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
    Ochiai T; Yasuda H; Araki M; Misawa K; Morishita S; Nudejima M; Hironaka Y; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
    Eur J Haematol; 2018 Jun; 100(6):544-549. PubMed ID: 29405428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.
    Kondo T; Okuno N; Naruse H; Kishimoto M; Tasaka T; Tsujioka T; Matsuoka A; Sugihara T; Tohyama Y; Tohyama K
    Leuk Lymphoma; 2008 Sep; 49(9):1784-91. PubMed ID: 18661406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
    Kutti J; Ridell B
    Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
    Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
    Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
    Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
    Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
    Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y; Lee JO; Bang SM
    J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.